Evolus (NASDAQ:EOLS – Get Free Report) and Cytosorbents (NASDAQ:CTSO – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Evolus and Cytosorbents, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evolus | 1 | 1 | 3 | 0 | 2.40 |
| Cytosorbents | 1 | 1 | 1 | 0 | 2.00 |
Evolus presently has a consensus price target of $21.25, indicating a potential upside of 237.30%. Cytosorbents has a consensus price target of $5.50, indicating a potential upside of 507.40%. Given Cytosorbents’ higher probable upside, analysts clearly believe Cytosorbents is more favorable than Evolus.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Evolus | -22.31% | -759.04% | -24.63% |
| Cytosorbents | -25.58% | -111.97% | -29.00% |
Earnings & Valuation
This table compares Evolus and Cytosorbents”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evolus | $266.27 million | 1.53 | -$50.42 million | ($0.98) | -6.43 |
| Cytosorbents | $35.60 million | 1.60 | -$20.72 million | ($0.17) | -5.33 |
Cytosorbents has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Evolus has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500.
Insider & Institutional Ownership
90.7% of Evolus shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 5.9% of Evolus shares are held by insiders. Comparatively, 7.3% of Cytosorbents shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Cytosorbents beats Evolus on 8 of the 14 factors compared between the two stocks.
About Evolus
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
About Cytosorbents
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.
